We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Curetis

Curetis GmbH develops and commercializes molecular diagnostic products that are designed to address the global challe... read more Featured Products: More products

Download Mobile App




Dedicated Blood Culture Diagnostics Cartridge Set for CE-IVD Marketing Release

By LabMedica International staff writers
Posted on 13 Apr 2016
An application cartridge for the dedicated identification of pathogens in blood cultures is set for CE-IVD market release.

The Curetis N.V. More...
(Holzgerlingen, Germany) Unyvero BCU Blood Culture Application Cartridge covers a broad range of diagnostic targets. These include 87 of the clinically most relevant pathogenic microorganisms, among them Gram positive and Gram negative bacteria, several fungi and atypical pathogens, as well as 16 related antibiotic resistance markers. The cartridge was introduced at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam (The Netherlands), April 8-12, 2016.

While the blood culture cartridge will be available as a consumable for Curetis’ Unyvero System, it is also compatible with the two most common systems and bottle types in the industry—Becton Dickinson (Franklin Lakes, NJ, USA) and bioMérieux (Marcy-l'Étoile, France)—as well as with other blood culture systems and bottles such as those produced by the Thermo Fisher Scientific (Milford, MA, USA) subsidiaries Oxoid and VersaTREK.

The Blood Culture Application Cartridge is the third Application Cartridge made for the Unyvero System. It follows the P55 Pneumonia Application launched in 2015 and the ITI Application for implant and tissue infections launched in 2014.

“We are excited to start marketing the third Application Cartridge for our Unyvero Platform,” said Dr. Achim Plum, chief commercial officer at Curetis. “With over 100 diagnostic targets covered by the Unyvero BCU cartridge, we believe to have the broadest available panel for suspected blood stream infections that can be used with a wide range of routine blood culture systems. The new Unyvero application will provide physicians with timely, comprehensive and actionable information in situations where every hour counts for the patient.”

Related Links:

Curetis N.V. 
Becton Dickinson
bioMérieux



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.